MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
=== Invasion === The U.S. launched its invasion of Panama on December 20, 1989. Although the killing of the Marine was the ostensible reason for the invasion, the operation had been planned for months before his death. The move was the largest military action by the U.S. since the Vietnam War, and included more than 27,000 soldiers, as well as 300 aircraft. The invasion began with a bombing campaign that targeted Noriega's private vehicles, and the PDF headquarters located in Panama City. Several slums in the middle of the city were destroyed as a result. The day after the invasion, Noriega's deputy Colonel Luis del Cid retreated with some soldiers to the mountains outside David City, after laying mines at the airport. Though this was part of a contingency plan for the invasion, del Cid quickly decided that the Panamanian military was not in a position to fight a guerrilla war against the U.S., and negotiated a surrender. Twenty-three U.S. soldiers were killed in the operation, including two that were killed by friendly fire; 324 soldiers were injured. Casualties among the Panamanian forces were much higher; between 300 and 845. The U.S. government reported between 202 and 250 civilian deaths; Americas Watch estimated 300 civilian deaths; and the United Nations estimated 500 civilian deaths. On December 29, the United Nations General Assembly voted, 75–20 with 40 abstentions, to condemn the invasion as a "flagrant violation of international law". According to a CBS poll, 92% of Panamanian adults supported the U.S. incursion, and 76% wished that U.S.
Lower Saxony is a coastal state (Land) in northwestern Germany. It is the second-largest state by land area, with 47,614 km2 (18,384 sq mi), and fourth-largest in population (8 million in 2021) among the 16 Länder of the Federal Republic of Germany. In rural areas, Northern Low Saxon and Saterland Frisian are spoken to varying degrees. Lower Saxony borders on (from north and clockwise) the North Sea, the states of Schleswig-Holstein, Hamburg, Mecklenburg-Vorpommern, Brandenburg, Saxony-Anhalt, Thuringia, Hesse and North Rhine-Westphalia, and the Netherlands. The state of Bremen forms two enclaves within Lower Saxony, one being the city of Bremen, the other its seaport, Bremerhaven (which is a semi-exclave, as it has a coastline). Lower Saxony thus borders more neighbours than any other single Bundesland. The state's largest cities are the state capital Hanover, Braunschweig (Brunswick), Oldenburg, Osnabrück, Wolfsburg, Göttingen, Salzgitter, Hildesheim, mainly situated in its central and southern parts, except Oldenburg. Lower Saxony is the only Bundesland that encompasses both maritime and mountainous areas. The northwestern area of the state, on the coast of the North Sea, is called East Frisia and the seven East Frisian Islands offshore are popular with tourists. In the extreme west of Lower Saxony is the Emsland, an economically emerging but rather sparsely populated area, once dominated by inaccessible swamps. The northern half of Lower Saxony, also known as the North German Plain, is almost invariably flat except for the gentle hills around the Bremen geestland.
There are relatively simple tests for radon gas. In some countries these tests are methodically done in areas of known systematic hazards. Radon detection devices are commercially available. Digital radon detectors provide ongoing measurements giving both daily, weekly, short-term and long-term average readouts via a digital display. Short-term radon test devices used for initial screening purposes are inexpensive, in some cases free. There are important protocols for taking short-term radon tests and it is imperative that they be strictly followed. The kit includes a collector that the user hangs in the lowest habitable floor of the house for two to seven days. The user then sends the collector to a laboratory for analysis. Long term kits, taking collections for up to one year or more, are also available. An open-land test kit can test radon emissions from the land before construction begins. Radon concentrations can vary daily, and accurate radon exposure estimates require long-term average radon measurements in the spaces where an individual spends a significant amount of time. Radon levels fluctuate naturally, due to factors like transient weather conditions, so an initial test might not be an accurate assessment of a home's average radon level. Radon levels are at a maximum during the coolest part of the day when pressure differentials are greatest. Therefore, a high result (over 4 pCi/L) justifies repeating the test before undertaking more expensive abatement projects. Measurements between 4 and 10 pCi/L warrant a long-term radon test.
The Church of Scotland (Lord High Commissioner) Bill is introduced into the House of Commons in order to lift the ban on Roman Catholics becoming the King's representative at the Church of Scotland's annual assembly, after Lady Elish Angiolini KC, a practising Catholic, was appointed to be Lord High Commissioner of the 2025 general assembly. Labour MP Kevin McKenna announces in the House of Commons that he is living with HIV. The UK government publishes a list of 100 proposed locations for potential new towns in England, with Housing Minister Matthew Pennycook saying work on them will begin before the next general election. 14 February – The UK government scraps the role of independent adviser on political violence, created before the last general election. 16 February – Former prime minister Sir John Major warns that the US's isolationist policy could be a threat to world democracy as it could leave a power vacuum and embolden states such as Russia and China. 17 February – Social Democratic and Labour Party leader Claire Hanna announces that the party will decline any invitations to the White House for St Patrick's Day celebrations due to Donald Trump's stance on the Gaza conflict. 19 February – Business Secretary Jonathan Reynolds faces calls for his resignation after he was accused of falsely saying he was a solicitor in his online CV. 20 February – Culture Secretary Lisa Nandy says she will raise concerns with BBC bosses over the documentary Gaza: How To Survive A War Zone, narrated by a 13-year-old boy who is the son of Hamas's deputy minister of agriculture.
Each year, approximately one million deaths are due to complications of cirrhosis, making cirrhosis the 11th most common cause of death globally. Cirrhosis and chronic liver disease were the tenth leading cause of death for men and the twelfth for women in the United States in 2001, killing about 27,000 people each year. The cause of cirrhosis can vary; alcohol and non-alcoholic fatty liver disease are main causes in western and industrialized countries, whereas viral hepatitis is the predominant cause in low and middle-income countries. Cirrhosis is more common in men than in women. The cost of cirrhosis in terms of human suffering, hospital costs, and lost productivity is high. Globally, age-standardized disability-adjusted life year (DALY) rates have decreased from 1990 to 2017, with the values going from 656.4 years per 100,000 people to 510.7 years per 100,000 people. In males DALY rates have decreased from 903.1 years per 100,000 population in 1990, to 719.3 years per 100,000 population in 2017; in females the DALY rates have decreased from 415.5 years per 100,000 population in 1990, to 307.6 years per 100,000 population in 2017. However, globally the total number of DALYs has increased by 10.9 million from 1990 to 2017, reaching the value of 41.4 million DALYs.
Sources: en.wikipedia.org
== Treatment == Debate is ongoing as to whether NTIS is an adaptive or maladaptive mechanism in response to physiological stress. Some sources indicate that NTIS is beneficial as an acute-phase response, but detrimental during the chronic phase of illness. Several trials have investigated a possible therapy for NTIS, but they yielded inconsistent and partly contradictory results. This may be due to the heterogeneity of investigated populations, and to the lack of a consistent definition of NTIS. Administering exogenous T3 and T4 has variable results, but overall seems to confer no improvements to health outcome. Administering TRH to patients with chronic illness, however, seems to normalize thyroid levels and improve catabolic function. When NTIS is caused by the normal fasting response to illness, early parenteral nutrition has been shown to attenuate alterations in thyroid hormone (TSH, T3, T4, rT3) levels, whereas late parenteral nutrition exacerbates it. Late parenteral nutrition, though, also reduced complications and accelerated recovery in one study.
=== Identification of the encoding gene === In 1949, a non-obese mouse colony being studied at the Jackson Laboratory produced a strain of obese offspring, suggesting that a mutation had occurred in a hormone regulating hunger and energy expenditure. Mice homozygous for the so-called ob mutation (ob/ob) ate voraciously and were massively obese. In the 1960s, a second mutation causing obesity and a similar phenotype was identified by Douglas Coleman, also at the Jackson Laboratory, and was named diabetes (db), as both ob/ob and db/db were obese. In 1990 Rudolph Leibel and Jeffrey M. Friedman reported mapping of the db gene. Consistent with Coleman's and Leibel's hypothesis, several subsequent studies from Leibel's and Friedman's labs and other groups confirmed that the ob gene encoded a novel hormone that circulated in blood and that could suppress food intake and body weight in ob and wild type mice, but not in db mice. In 1994, Friedman's laboratory reported the identification of the gene. In 1995, Jose F. Caro's laboratory provided evidence that the mutations in the mouse ob gene did not occur in humans. Furthermore, since ob gene expression was increased, not decreased, in human obesity, it suggested resistance to leptin to be a possibility. At the suggestion of Roger Guillemin, Friedman named this new hormone "leptin" from the Greek lepto meaning thin. Leptin was the first fat cell-derived hormone (adipokine) to be discovered.
μ is the dynamic viscosity of the fluid (Pa·s = N·s/m2 = kg/(m·s)); Q is the volumetric flow rate, used here to measure flow instead of mean velocity according to Q = π/4Dc2<v> (m3/s). Note that this laminar form of Darcy–Weisbach is equivalent to the Hagen–Poiseuille equation, which is analytically derived from the Navier–Stokes equations.
It is believed that the first documented European to explore the east coast of Canada was Norse explorer Leif Erikson. In approximately 1000 AD, the Norse built a small short-lived encampment that was occupied sporadically for perhaps 20 years at L'Anse aux Meadows on the northern tip of Newfoundland. No further European exploration occurred until 1497, when seafarer John Cabot explored and claimed Canada's Atlantic coast in the name of Henry VII of England. In 1534, French explorer Jacques Cartier explored the Gulf of Saint Lawrence where, on July 24, he planted a 10-metre (33 ft) cross bearing the words, "long live the King of France", and took possession of the territory New France in the name of King Francis I. The early 16th century saw European mariners with navigational techniques pioneered by the Basque and Portuguese establish seasonal whaling and fishing outposts along the Atlantic coast. In general, early settlements appear to have been short-lived due to a combination of the harsh climate, problems with navigating trade routes and competing outputs in Scandinavia. In 1583, Sir Humphrey Gilbert, by the royal prerogative of Queen Elizabeth I, founded St John's, Newfoundland, as the first North American English seasonal camp. In 1600, the French established their first seasonal trading post at Tadoussac along the Saint Lawrence. French explorer Samuel de Champlain arrived in 1603 and established the first permanent year-round European settlements at Port Royal (in 1605) and Quebec City (in 1608).
==== Screening for ubiquitin ligase substrates ==== Deregulation of E3-substrate interactions is a key cause of many human disorders, therefore identifying E3 ligase substrates is crucial. In 2008, 'Global Protein Stability (GPS) Profiling' was developed to discover E3 ubiquitin ligase substrates. This high-throughput system made use of reporter proteins fused with thousands of potential substrates independently. By inhibition of the ligase activity (through the making of Cul1 dominant negative thus renders ubiquitination not to occur), increased reporter activity shows that the identified substrates are being accumulated. This approach added a large number of new substrates to the list of E3 ligase substrates.
Sources: en.wikipedia.org
=== Islamic modernism and Islamic socialism === Gaddafi rejected the secularist approach to Arab nationalism that had been pervasive in Syria, with his revolutionary movement placing a far stronger emphasis on Islam than previous Arab nationalist movements had done. He deemed Arabism and Islam to be inseparable, referring to them as "one and indivisible", and called on the Arab world's Christian minority to convert to Islam. He insisted that Islamic law should be the basis for the law of the state, blurring any distinction between the religious and secular realms. He desired unity across the Islamic world, and encouraged the propagation of the faith elsewhere; on a 2010 visit to Italy, he paid a modelling agency to find 200 young Italian women for a lecture he gave urging them to convert. According to the Gaddafi biographer Jonathan Bearman, in Islamic terms Gaddafi was a modernist rather than a fundamentalist, for he subordinated religion to the political system rather than seeking to Islamicise the state as Islamists sought to do. He was driven by a sense of "divine mission", believing himself a conduit of God's will, and thought that he must achieve his goals "no matter what the cost". His interpretation of Islam was nevertheless idiosyncratic, and he clashed with conservative Libyan clerics. Many criticized his attempts to encourage women to enter traditionally male-only sectors of society, such as the armed forces.
=== Disorder in the bound state (fuzzy complexes) === Intrinsically disordered proteins can retain their conformational freedom even when they bind specifically to other proteins. The structural disorder in bound state can be static or dynamic. In fuzzy complexes structural multiplicity is required for function and the manipulation of the bound disordered region changes activity. The conformational ensemble of the complex is modulated via post-translational modifications or protein interactions. Specificity of DNA binding proteins often depends on the length of fuzzy regions, which is varied by alternative splicing. Some fuzzy complexes may exhibit high binding affinity, although other studies showed different affinity values for the same system in a different concentration regime.
== Biochemistry == Psilocin was first reported in this species in Benedict et al., 1962, and a few years later, Leung and Paul would report the related compound baeocystin, isolated from saprophytic culture, as well as the desmethyl metabolite norbaeocystin. Beug and Bigwood (1981) also reported on the concentrations of these compounds in Psilocybe baeocystis using reverse-phase HPLC and thin-layer chromatography. Concentration ranges for psychoactive compounds from these studies were reported to be 0.15–0.85% psilocybin, up to 0.59% psilocin, and up to 0.10% baeocystin.
== Substrate depletion == In 2022, it was discovered that aminoacyl-tRNA synthetases may incorporate alternative amino acids during shortages of their precursors. In particular, tryptophanyl-tRNA synthetase (WARS1) will incorporate phenylalanine during tryptophan depletion, essentially inducing a W>F codon reassignment. Depletion of the other substrate of aminoacyl-tRNA synthetases, the cognate tRNA, may be relevant to certain diseases, e.g. Charcot–Marie–Tooth disease. It was shown that CMT-mutant glycyl-tRNA synthetase variants are still able to bind tRNAGly but fail to release it, leading to depletion of the cellular pool of glycyl-tRNAGly, what in turn results in stalling of the ribosome on glycine codons during mRNA translation.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.